ViroPharma Inc. (VPHM)
Name: ViroPharma Inc. (VPHM)
Web Site: http://www.viropharma.com
Brief Description: ViroPharma Incorporated, a pharmaceutical company, engages in the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. It markets and sells Vancocin Pulvules HCl, the oral capsule formulation, in the United States and its territories. Oral Vancocin is a potent antibiotic to treat antibiotic-associated pseudomembranous and enterocolitis. The company focuses on product development activities on viral diseases, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. Its products under core development program include CMV with an initial focus on CMV infections in recipients of hematopoietic stem cell/bone marrow transplants, and HCV. Noncore development programs target picornaviruses with intranasal pleconaril. The company has strategic relationships with Glaxo SmithKline, Wyeth, Schering-Plough, and Sanofi-Aventis. ViroPharma was incorporated in 1994 and is based in Exton, Pennsylvania.
05/05/2006 - Downgraded to Neutral rating
ANALYST OPINION: We downgrade ViroPharma Inc. (VPHM), to Neutral rating. [Contact the Analyst]
INVESTMENT PERFORMANCE: After a spike of over +120% since our initiation of coverage, VPHM was seriously punished for it undiversified revenue base. In March 2006, VPHM has been informed by FDA that the agency may waive certain drug trials measuring bio-equivalency for a potential generic product. After this announcement VPHM's shares droped on fears that lead drug Vancocin could be facing generic competition sooner than expected. Moreover the Q1FY06 results reported yesterday are below our expectations. We downgrade VPHM to Neutral rating and also drop coverage due to increasing analyst coverage on this stock.
07/25/05 - Initiated with Buy rating.
Contact the Analyst
|